Doctors from Boston University and Harvard Medical School are developing a potentially game-changing technology for people with type 1 diabetes.
The goal of our program is to improve the lives of all people living with type 1 diabetes (T1D). Working closely with key players across the T1D ecosystem – patients, physicians, caregivers, researchers, government agencies, funders, pharmaceutical companies, device makers, insurers, and community organizations – we seek to improve care and ultimately prevent the disease.
Helmsley supports innovative projects that are high-risk, high-reward, and have a long-term vision. We encourage bold thinking and new approaches, supporting projects that others cannot fund but have a clear impact on the lives of people with T1D. We consider ourselves an active partner with our grantees, rather than simply a funder. Together, we envision a T1D environment that fosters collaboration and data-sharing.